过敏治疗及其相关的基础免疫学研究进展  

Research Progress on Allergy Treatments and Its Related Basic Immunology

作　　者：孙仁山[1] 伍津津[1] 

机构地区：[1]重庆市第三军医大学附属大坪医院野战外科研究所皮肤性病科,重庆400042

出　　处：《中国皮肤性病学杂志》2010年第11期983-985,共3页The Chinese Journal of Dermatovenereology

基　　金：国家自然科学基金资助项目(30972647)

摘　　要：近年关于过敏治疗和相关的基础免疫学研究发展迅速,针对Ⅰ型超敏反应的研究措施有抗IgE治疗、合成肽免疫治疗、融合蛋白治疗、置换肽免疫治疗、DNA疫苗和免疫佐剂融合治疗等。过敏相关的免疫学研究进展包括变应原和FcγRI融合蛋白,可使抗原提呈细胞增加抗原表位呈现,诱导调节性T细胞的分化;一种幽门螺杆菌的毒性因子,可以刺激小鼠Th2反应性向Th1反应性的转化;特应性皮炎患者皮肤对金黄色葡萄球菌的易感增强,部分原因是对β-防御素的动员减弱;特应性体质者Th2反应性增强,导致了其Th1细胞的凋亡增加等。In recent years, there are rapid progresses on allergic treatments and the related basic immunology. Investigators have developed several therapeutic modalities potentially applicable to the treatment and eventual prevention of allergy. Among the therapeutic options currently under investigation, there are anti-IgE therapy, synthetic peptide immunotherapy, fusion protein immunotherapy, DNA vaccine and immunologic adjuvants nostimulatory sequences linked to allergens. These novel forms of treatment for allergic disease hold promise for the safe and effective treatment and prevention of allergy in the future. Research progresses in the immu- nologic mechanisms of allergic disease include the modulation of Th2 responses by specific transcription factors and receptors associated with the innate immunity, underscoring the importance of the interactions between adaptive and innate immune mechanisms.

关 键 词：过敏治疗 Th1反应 TH2反应 

分 类 号：R751.05[医药卫生—皮肤病学与性病学]